News
Sanofi to buy Blueprint Medicines for over $9 billion
As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint Medicines in a deal worth $9.1 billion (£6.7 billion) in cash, with an additional $400 million on offer in performance milestone payments.
Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...
Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...
The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...
Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback